Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

PHASE3CompletedINTERVENTIONAL
Enrollment

623

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

June 11, 2020

Study Completion Date

June 11, 2020

Conditions
Keratoconjunctivitis SiccaDry Eye
Interventions
DRUG

Tavilermide ophthalmic solution

BID topical dosing

OTHER

Placebo

BID topical dosing

Trial Locations (22)

28150

Tavilermide Investigational Site, Shelby

33067

Tavilermide Investigational Site, Coral Springs

33437

Tavilermide Investigational Site, Boynton Beach

34209

Tavilermide Investigational Site, Bradenton

34474

Tavilermide Investigational Site, Ocala

37205

Tavilermide Investigational Site, Nashville

37803

Tavilermide Investigational Site, Maryville

40206

Tavilermide Investigational Site, Louisville

40509

Tavilermide Investigational Site, Lexington

45040

Tavilermide Investigational Site, Mason

45236

Tavilermide Investigational Site, Cincinnati

46290

Tavilermide Investigational Site, Indianapolis

51104

Tavilermide Investigational Site, Sioux City

53142

Tavilermide Investigational Site, Kenosha

57701

Tavilermide Investigational Site, Rapid City

63131

Tavilermide Investigational Site, St Louis

78248

Tavilermide Investigational Site, San Antonio

80120

Tavilermide Investigational Site, Littleton

80528

Tavilermide Investigational Site, Fort Collins

85032

Tavilermide Investigational Site, Phoenix

90013

Tavilermide Investigational Site, Los Angeles

92663

Tavilermide Investigational Site, Newport Beach

All Listed Sponsors
lead

Mimetogen Pharmaceuticals USA, Inc.

INDUSTRY